CHF medications: Difference between revisions
(Created page with " RA RCW SVR BP CO Isordil60 - - (-) - -+ hydral100 ~ ~ - +- ++ hy (MR/AI) - -- ++ -+ +- ACEI - - - +- + Minoxidil ~ ~ -- +- ++ Carvedilol: decreases mortality 67% Digo...") |
(Text replacement - "qd" to "QD") |
||
| (16 intermediate revisions by 5 users not shown) | |||
| Line 1: | Line 1: | ||
{| class="wikitable" | |||
|- | |||
|'''Agent''' | |||
|'''RA''' | |||
|'''RCW''' | |||
|'''SVR''' | |||
|'''BP''' | |||
|'''CO''' | |||
|- | |||
| [[Isordil]] 60 | |||
| - | |||
| - | |||
| (-) | |||
| - | |||
| -/+ | |||
|- | |||
| [[Hydralazine]] 100 | |||
| ~ | |||
| ~ | |||
| - | |||
| +/- | |||
| ++ | |||
|- | |||
| hy (MR/AI) | |||
| - | |||
| -- | |||
| ++ | |||
| -/+ | |||
| +/- | |||
|- | |||
| [[ACEI]] | |||
| - | |||
| - | |||
| - | |||
| +/- | |||
| + | |||
|- | |||
| Minoxidil | |||
| ~ | |||
| ~ | |||
| -- | |||
| +/- | |||
| ++ | |||
|} | |||
ACEI GREAT mortality benefit | *[[Carvedilol]]: decreases mortality 67% | ||
*[[Digoxin]]: decrease syx/hospitaliz | |||
*Aldactone in Class IV decrease mortality | |||
*[[Isordil]]: cor. VD; +BP if ischemia | |||
*ISDN/HYDRA. decreased mortality in CHF | |||
*ACEI GREAT mortality benefit | |||
==Target Doses== | ==Target Doses== | ||
*[[Hydralazine]]: 100 TID start 25 | |||
*Isordil: 60-80 TID | |||
*[[Captopril]]: 100 TID start 12.5 | |||
*[[Lisinopril]]/[[enalapril]]: 10 BID class II/III | |||
**20 BID class IV | |||
*[[Carvedilol]] 25 BID; 50 BID if >80kg | |||
*[[Digoxin]]: varies | |||
*[[Spironolactone]] 25-50 QD | |||
*[[Enalapril]] 1.25mg IV | |||
*[[Nitroglycerin]] (Initial dose 5-10ug/min, increased every 3-5 minute to dose range 10-200ug/min) | |||
*[[Nitroprusside]] (Initial dose 5-10ug/min, increased every 3-5 minute to dose range 5-400ug/min) | |||
^Consider when need afterload reduction | |||
==See Also== | ==See Also== | ||
[[Congestive Heart Failure (CHF)]] | |||
[[Category:Cardiology]] | |||
[[Category:Pharmacology]] | |||
[[Category: | |||
Latest revision as of 10:17, 7 July 2017
| Agent | RA | RCW | SVR | BP | CO |
| Isordil 60 | - | - | (-) | - | -/+ |
| Hydralazine 100 | ~ | ~ | - | +/- | ++ |
| hy (MR/AI) | - | -- | ++ | -/+ | +/- |
| ACEI | - | - | - | +/- | + |
| Minoxidil | ~ | ~ | -- | +/- | ++ |
- Carvedilol: decreases mortality 67%
- Digoxin: decrease syx/hospitaliz
- Aldactone in Class IV decrease mortality
- Isordil: cor. VD; +BP if ischemia
- ISDN/HYDRA. decreased mortality in CHF
- ACEI GREAT mortality benefit
Target Doses
- Hydralazine: 100 TID start 25
- Isordil: 60-80 TID
- Captopril: 100 TID start 12.5
- Lisinopril/enalapril: 10 BID class II/III
- 20 BID class IV
- Carvedilol 25 BID; 50 BID if >80kg
- Digoxin: varies
- Spironolactone 25-50 QD
- Enalapril 1.25mg IV
- Nitroglycerin (Initial dose 5-10ug/min, increased every 3-5 minute to dose range 10-200ug/min)
- Nitroprusside (Initial dose 5-10ug/min, increased every 3-5 minute to dose range 5-400ug/min)
^Consider when need afterload reduction
